{"id":"NCT04228783","sponsor":"Janssen Vaccines & Prevention B.V.","briefTitle":"A Study of 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BN-Filo in Adult Participants","officialTitle":"A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Evaluate the Immunogenicity, Safety, Reactogenicity, and Consistency of a Heterologous 2-dose Vaccine Regimen Using 3 Consecutive Lots of Ad26.ZEBOV and MVA-BNÂ®-Filo in Adult Participants","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2020-02-18","primaryCompletion":"2022-04-25","completion":"2022-04-25","firstPosted":"2020-01-14","resultsPosted":"2023-05-17","lastUpdate":"2025-05-25"},"enrollment":974,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"PREVENTION"},"conditions":["Ebola"],"interventions":[{"type":"BIOLOGICAL","name":"Ad26.ZEBOV","otherNames":[]},{"type":"BIOLOGICAL","name":"MVA-BN-Filo","otherNames":[]},{"type":"BIOLOGICAL","name":"Placebo","otherNames":[]}],"arms":[{"label":"Active Vaccine: Group 1 (Ad26.ZEBOV-Lot A, MVA-BN-Filo-Lot 1)","type":"EXPERIMENTAL"},{"label":"Active Vaccine: Group 2 (Ad26.ZEBOV-Lot B, MVA-BN-Filo-Lot 2)","type":"EXPERIMENTAL"},{"label":"Active Vaccine: Group 3 (Ad26.ZEBOV-Lot C, MVA-BN-Filo-Lot 3)","type":"EXPERIMENTAL"},{"label":"Control Vaccine: Group 4 (Placebo)","type":"PLACEBO_COMPARATOR"},{"label":"Booster Cohort: Group 5 (Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV)","type":"EXPERIMENTAL"},{"label":"Booster Cohort: Group 6 (Placebo)","type":"PLACEBO_COMPARATOR"}],"summary":"The purpose of this study is to demonstrate that the paired 2-dose vaccine regimens from 3 consecutively manufactured lots of Adenovirus serotype 26 encoding the Ebola virus Mayinga glycoprotein (Ad26.ZEBOV) as Dose 1 and 3 consecutively manufactured lots of Modified Vaccinia Ankara Bavarian Nordic vector encoding multiple filovirus proteins (MVA-BN-Filo) including the ebola virus mayinga glycoprotein as Dose 2, administered at a 56-day interval, induce an equivalent humoral immune response.","primaryOutcome":{"measure":"Geometric Mean Concentrations (GMCs) of Binding Antibody Levels Against the Ebola Virus Glycoprotein (EBOV GP) as Measured by Enzyme-linked Immunosorbent Assay (ELISA) at 21 Days Post Vaccination 2","timeFrame":"21 Days Post Vaccination 2 (Day 78)","effectByArm":[{"arm":"Ad26.ZEBOV(Lot A), MVA-BN-Filo (Lot 1) (Group 1)","deltaMin":11077,"sd":null},{"arm":"Ad26.ZEBOV(Lot B), MVA-BN-Filo (Lot 2) (Group 2)","deltaMin":12223,"sd":null},{"arm":"Ad26.ZEBOV(Lot C), MVA-BN-Filo (Lot 3) (Group 3)","deltaMin":11818,"sd":null},{"arm":"Placebo, Placebo (Group 4)","deltaMin":null,"sd":null},{"arm":"Ad26.ZEBOV, MVA-BN-Filo, Ad26.ZEBOV (Group 5)","deltaMin":18877,"sd":null},{"arm":"Placebo, Placebo, Placebo (Group 6)","deltaMin":null,"sd":null}],"pValues":[{"comp":"OG000 vs OG001","p":null},{"comp":"OG000 vs OG002","p":null},{"comp":"OG001 vs OG002","p":null}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":true,"inclusionCount":6,"exclusionCount":7},"locations":{"siteCount":7,"countries":["United States"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":4,"n":287},"commonTop":["Covid-19","Ligament Sprain"]}}